A highly stimulating programme on pharmaceutical R&D and BD&L in the form of a boardgame called Risky Business.
Read more…
Courses for R&D portfolio managers and R&D project leaders and teams to improve strategic decision making.
Read more…
Customised ProgammesWe tailor existing courses on strategy and decision analysis or create new courses for specific training needs.
Read more…
Check the Training Calendar for course offerings at The Catenion Academy’s facilities in Berlin.
Download the Risky Business brochure (
350 KB).
For direct information or to book a Risky Business course, contact an instructor.
"As a Biotech Cluster Development organization, one of the purposes of BioM is to be the first point of contact for start-ups and outside firms in the life science sector. The Risky Business workshop was a wonderful way to facilitate this and bring people together from different professional affiliations with common interests in a very collaborative way. Within the format of a Business Development forum the game connected people from many different companies who then shared ideas regarding industry problems and solutions. Risky Business proofed to be an interactive way to open up dialogue between companies and institutions of our Biotechnology Cluster."
Dr. Stephanie Wehnelt
Manager Marketing & Communication
BioM Biotech Cluster Development GmbH

Pharmaceutical companies make some of the biggest gambles of any industry: multi−million, even multi−billion dollar investments on a new drug. These investments can take more than a decade to play out. Scientific and technical barriers produce a high failure rate: Only one in ten new Phase I drugs make it to the market.
It appears obvious that partnering through business development and licensing can reduce the risks. However, key employees in R&D, BD&L, finance, sales & marketing, manufacturing and other areas often have a limited appreciation of how these risks actually strike or how to reduce them.
This course gives professionals from inside and outside the pharmaceutical industry a much better understanding of how the R&D and BD&L processes operate. Participants get involved in a board game that has been developed specifically to mimic the pharmaceutical industry. The game enables players to absorb the complexities of R&D and BD&L easily and quickly!
There are two courses for Risky Business.
This Risky Business course provides an engaging team experience with the challenge of taking the roles of an executive team. The course focuses on the essential mechanics of R&D, BD&L and provides insights into the impact of different strategies.
This version runs for 4 to 5 hours, including short presentations on such topics as:
Fees: € 5.000 + VAT per group of 12 to 24 participants.
In this version, the game is played in a morning session.
The afternoon session offers an in–depth workshop and presentation on how to use the insights of the game to review or develop a strategy.
It is particularly suited to prepare a team to develop, review or adapt a R&D or BD&L strategy. Specific aspects of a company’s strategy can be concentated on through workshops, simulations or breakout groups addressing such topics as:
Further details upon request.
Fees: start at € 8.000 + VAT per group of 12 to 24 participants, depending on the level of customisation.
Each participant takes on the role of a pharmaceutical executive. The game gives them the experience of a multi−year drug development process, the creation of corporate strategies, management of the R&D pipeline, and the execution of partnering strategies (from searching for partners to negotiations).
Each game lasts three to five hours. Participants experience project successes and failures, and watch licensing deals produce value or write−offs. They therefore see the benefits and risks of going it alone vs. partnering in development, manufacturing, and marketing and sales.
Risky Business can be played by professionals from inside and outside the pharmaceutical industry who want to gain strategic insight into the financial decisions of R&D and BD&L.
The game can be played by all levels, from the executive board to operational functions.
Companies typically play Risky Business at departmental retreats, strategic planning processes, and human resource programmes, as well as global company meetings.
Outsiders to the pharmaceutical industry can also benefit from playing Risky Business. The game has been played by patient advocacy groups and patients, the press, politicians and other stakeholders in the healthcare system. The game helps all these groups better understand the complexities of bringing promising new drugs to market.
Risky Business is simultaneously a fun experience and a challenging team exercise, one that deepens strategic thinking and understanding across all functions and levels in pharmaceutical companies.
The game is an effective way for pharmaceutical professionals to become more knowledgeable about their roles in the two core processes of their company: R&D and BD&L
For people outside the industry, Risky Business provides deep insights into the mechanics of pharmaceutical R&D, progress, risk and failure – areas that are not always fully understood.
Risky Business helps managers get to know each other in critical ways. It provides a safe environment for highlighting problems, staging productive conflicts and, more importantly, learning how to resolve them to produce the best outcome for a pharmaceutical company.
Research on motivation has found that playing games is far more engaging than listening to lectures. Studies suggest that inspiring people to learn new things requires challenge, curiosity, fantasy and control. Risky Business is built on these principles.
Risky Business Game created by Jesper Lyng Jensen, www.rbgame.com.